Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Teeth Whitening

Biotech Leaders, Patient Advocates Highlight Cutting-Edge HIV/AIDS Therapies, Need For Next Generation Treatments
Leaders in biotechnology research and patient advocacy joined forces today at the 2009 BIO International Convention to discuss the latest breakthroughs in HIV/AIDS treatments. Following a keynote speech by Sir Elton John focused on the needs of the HIV/AIDS community, representatives of biotech companies previewed the next generation of treatments while patient advocates reiterated the need for new therapies, particularly for those who have developed resistance to existing medications. Researchers are developing new therapies that are more effective in treating HIV/AIDS, including an AIDS vaccine and new methods of delivery that hold the potential to increase patient compliance.
generic viagra online
Atherosclerosis Vaccine Development Receives EU Support
The atherosclerosis vaccine development program by
plastic surgery before after
News of the day
Obama Pitches Health Reform To Public And Congress, Argues Inaction Is Unacceptable
"With many Americans growing anxious about his plans to overhaul the nation"s healthcare system, President Obama on Wednesday sought to lay out in personal terms how they stand to gain from the legislation that he has made one of the top goals of his presidency," the Los Angeles Times reports. He used the speech to reach out to people who already have insurance, arguing that skyrocketing costs must be slowed and that inaction would hobble businesses and families alike. In making the case for health reform to the American public, however, Obama described specific policy ideas and "relied on jargon that Washington insiders embrace but that might leave the typical television viewer mystified" (Nicholas, Parsons and Levey, 7/23).
Cardiovascular

Medtronic's Corevalve Shows Subclavian Access Success In Patients Contraindicated For Femoral Approach

Medtronic, Inc. (NYSE: MDT) announced new data presented today on the safety and effectiveness of Medtronic"s CoreValve system via a novel, subclavian approach. The data reported procedural success of 100 percent; 24- hour survival of 100 percent; and 30-day survival of 89 percent. The available 30-day analysis also demonstrated clinical improvement in heart failure symptoms with 76 percent of the patients gaining at least a oneņ€stage NYHA class and oneņ€third improving by at least two stages. Medtronic"s marketņ€leading CoreValve system was designed to allow the implant of a replacement heart valve in patients with aortic stenosis who are at high or prohibitive surgical risk. The system enables a catheterņ€based implant via a peripheral blood vessel, traditionally the femoral artery. A significant subset of patients, however, have compromised peripheral arteries, which prevents the use of the femoral approach. Uniquely, the delivery system of the CoreValve device is small enough to allow an alternative approach via the subclavian artery beneath the collar bone. "The combination of unique valve design and controlled deliverability have contributed to the tremendous success of the Medtronic CoreValve system using the femoral approach," said John Liddicoat M.D., vice president and general manager of the CardioVascular Structural Heart division at Medtronic. "These new data suggest that a subclavian artery approach could address yet another underņ€served patient population. We are committed to gather the necessary clinical experience and evidence to support the routine use of a subclavian approach in those for whom a femoral approach is not possible." The data presented today at the PCR interventional cardiology meeting in Barcelona reported on data from 74 patients for whom subclavian access was used within the CoreValve Extended Evaluation Registry, an observational study which closed in January 2009. The average age of the patients was 81.4. Moreover, the average Logistic EuroSCORE (a measure which predicts risk of procedural mortality based upon patient status) was notably high at 28.4%. Medtronic


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009